Gyre Therapeutics (GYRE) EPS (Weighted Average and Diluted) (2010 - 2026)
Gyre Therapeutics (GYRE) reported EPS (Weighted Average and Diluted) of -$0.1 for Q1 2026, down 400.0% on a QoQ basis from -$0.02 in Q4 2025.
Gyre Therapeutics (GYRE) has 10 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.1 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) changed N/A year-over-year to -$0.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.09 (down 550.0% YoY) and the FY2025 annual result came in at $0.02, down 60.0% from the prior year.
- EPS (Weighted Average and Diluted) eased to -$0.1 in Q1 2026 per GYRE's latest filing, from -$0.02 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $1.64 in Q2 2022 and bottomed at -$1.51 in Q4 2023.
- The 5-year median for EPS (Weighted Average and Diluted) is $0.01 (2024), against an average of -$0.12.
- Peak annual rise in EPS (Weighted Average and Diluted) reached 356.25% in 2022, while the deepest fall reached 100.0% in 2022.
- Tracing GYRE's EPS (Weighted Average and Diluted) over 5 years: stood at -$1.28 in 2022, then retreated by 17.97% to -$1.51 in 2023, then jumped by 100.66% to $0.01 in 2024, then tumbled by 300.0% to -$0.02 in 2025, then sank by 400.0% to -$0.1 in 2026.
- Per Business Quant, the three latest GYRE EPS (Weighted Average and Diluted) figures stand at -$0.1 (Q1 2026), -$0.02 (Q4 2025), and $0.03 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | -0.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.10 |
| Dec 31, 2025 | -0.02 |
| Sep 30, 2025 | 0.03 |
| Sep 30, 2024 | 0.01 |
| Jun 30, 2024 | 0.01 |
| Mar 31, 2024 | 0.03 |
| Dec 31, 2023 | -1.51 |
| Sep 30, 2023 | 0.05 |
| Jun 30, 2023 | 0.02 |
| Mar 31, 2023 | 0.03 |
| Dec 31, 2022 | -1.28 |
| Sep 30, 2022 | -0.16 |
| Jun 30, 2022 | 1.64 |
| Mar 31, 2022 | -0.46 |
| Dec 31, 2021 | -0.64 |
| Sep 30, 2021 | -0.80 |
| Jun 30, 2021 | -0.64 |
| Sep 30, 2013 | -0.38 |
| Jun 30, 2013 | -0.37 |
| Mar 31, 2013 | -0.24 |
| Dec 31, 2012 | -0.47 |
| Sep 30, 2012 | -0.24 |
| Jun 30, 2012 | 0.43 |
| Mar 31, 2012 | 0.07 |
| Dec 31, 2011 | -0.29 |
| Sep 30, 2011 | -0.27 |
| Jun 30, 2011 | -0.07 |
| Mar 31, 2011 | 0.41 |
| Dec 31, 2010 | -0.07 |
| Sep 30, 2010 | 0.08 |
| Jun 30, 2010 | 0.13 |